You are here
SENEX BIOTECHNOLOGY, INC.
UEI: G8XKMW3DYMQ6
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition
Amount: $400,000.00Dysregulation of the PI3K/AKT/mTOR pathway is one of the most common genetic alterations in cancer, found in more than one third of all solid tumors. Inhibitors of the key components of this pathway ( ...
SBIRPhase I2022Department of Health and Human Services National Institutes of Health -
CDK8/19 inhibitors for therapy of advanced prostate cancer
Amount: $1,977,275.00The growth of most prostate cancers is driven by androgen receptor (AR), a transcriptional regulator that has both tumor-promoting and tumor-suppressive activities. Aggressive prostate cancer is treat ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Enhancing cytarabine efficacy in leukemia through CDK inhibition
Amount: $299,891.00Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeuti ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
CDK inhibitor for the treatment of HER breast cancer
Amount: $299,993.00Approximately of breast cancers overexpress oncogenic tyrosine kinase receptor HER NEU Patients with metastatic HER cancer typically receive HER targeting monoclonal antibodies trastuzumab a ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Targeting CDK for the treatment of vein graft failure
Amount: $299,151.00The long term efficacy of vein graft transplantation the most effective surgical treatment for occlusive vascular disease is limited by eventual vein graft occlusion A major cause of vein graft fai ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
CDK8/19 inhibitors for therapy of advanced prostate cancer
Amount: $240,750.00DESCRIPTION provided by applicant All existing forms of androgen deprivation therapy ADT the backbone of systemic prostate cancer PCa treatment involve inhibition of either ligand production ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
CDK3-inhibiting anticancer agents
Amount: $1,548,102.00DESCRIPTION (provided by applicant): This Phase II SBIR project is aimed at developing a novel type of drugs, termed SNX9-class compounds, with a unique combination of two anticancer activities. The f ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
CDK3-inhibiting anticancer agents
Amount: $107,000.00DESCRIPTION (provided by applicant): This Phase I SBIR project is aimed at developing a novel type of anticancer drugs, termed SNX9- class compounds. These compounds have a dual activity: (i) inhibiti ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Small Molecules Inducing BTG1 Transcription
Amount: $107,001.00DESCRIPTION (provided by applicant): BTG1 is a transcription regulatory protein that interacts with different transcription factors and nuclear receptors. BTG1 acts as a tumor suppressor and as a medi ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Inhibitors of disease-promoting activities of senescence
Amount: $802,501.00DESCRIPTION (provided by applicant): This project is aimed at developing a new class of drugs, which act by inhibiting pathogenic activities of senescent cells. Cell senescence occurring as a result o ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health
